Wellington Management Group LLP Purchases New Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Wellington Management Group LLP bought a new stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 100,613 shares of the company’s stock, valued at approximately $1,609,000. Wellington Management Group LLP owned approximately 0.09% of Centessa Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of CNTA. State Street Corp acquired a new stake in shares of Centessa Pharmaceuticals during the third quarter worth approximately $777,000. RTW Investments LP acquired a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter valued at $800,000. Point72 Asset Management L.P. increased its stake in shares of Centessa Pharmaceuticals by 54.1% in the third quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock worth $43,423,000 after acquiring an additional 953,659 shares during the last quarter. Janus Henderson Group PLC acquired a new position in shares of Centessa Pharmaceuticals in the third quarter worth $20,698,000. Finally, HighVista Strategies LLC purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter worth $737,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Insider Buying and Selling

In other news, insider Karen M. Anderson sold 10,624 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $17.32, for a total transaction of $184,007.68. Following the sale, the insider now directly owns 71,525 shares in the company, valued at approximately $1,238,813. The trade was a 12.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Gregory M. Weinhoff sold 16,619 shares of Centessa Pharmaceuticals stock in a transaction on Wednesday, September 25th. The stock was sold at an average price of $15.69, for a total transaction of $260,752.11. Following the sale, the insider now owns 206,750 shares in the company, valued at $3,243,907.50. This represents a 7.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 374,642 shares of company stock valued at $6,375,876 over the last three months. 11.59% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on CNTA shares. B. Riley assumed coverage on Centessa Pharmaceuticals in a research note on Thursday, September 19th. They issued a “buy” rating and a $33.00 target price on the stock. BMO Capital Markets lifted their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, September 16th. Jefferies Financial Group increased their price target on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. Finally, Guggenheim increased their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $25.83.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA opened at $16.51 on Thursday. The firm has a market capitalization of $2.18 billion, a PE ratio of -10.79 and a beta of 1.52. Centessa Pharmaceuticals plc has a 1 year low of $6.65 and a 1 year high of $18.97. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm’s fifty day simple moving average is $16.58 and its 200 day simple moving average is $13.49.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.05. On average, sell-side analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.